Table 2.
Summary of introductive drugs that may induce pyroptosis in several cancers
| Cancer types | Drugs | Mechanisms of pyroptosis activation | References |
|---|---|---|---|
| Lung cancer | L61H10 | Cell Cycle Arrest/NF-κB/GSDME | [241] |
| 13d, a derivative of EF24 | NF-κB inhibition and lower cytotoxicity | [234] | |
| Paclitaxel and Cisplatin | Caspase-3/GSDME | [275] | |
| Hepatocellular carcinoma | Cannabidiol | Caspase-3/GSDME | [227] |
| Miltirone | ROS/Bax/Caspase-3/GSDME | [228] | |
| Sorafenib | Caspase-1/GSDMD in macrophages | [226] | |
| Colorectal cancer | Lobaplatin | ROS and JNK/Caspase-9/Caspase-3/GSDME | [231] |
| FL118 | NLRP3/Caspase-1/GSDMD | [235] | |
| A438079 | NLRP3/Caspase1/GSDMD pathway by inhibiting P2X7R | [236] | |
| Gastric cancer | Famotidine | NLPR3/GSDME | [237] |
| BIX-01294 | Caspase-3/GSDME | [238] | |
| Diosbulbin-B (DB) | PD-L1/NLRP3/Caspase1/GSDMD | [239] | |
| Breast Cancer | DHA | NF-κB/Caspase1/GSDMD | [240] |
| Cisplatin | MEG3/NLRP3/Caspase-1/GSDMD | [222] | |
| Melanoma cancer | Doxorubicin | eEF-2K/GSDME | [272] |
| ESCC | BI2536 and Cisplatin | Caspase-3/GSDME | [275] |
| Ovarian cancer | α-NETA | Caspase-4/GSDMD | [215] |